Biology of Aging, Workshop Webinar Series - Session 2. “Preclinical to clinical trials.” October 19 from 3-4:30pm Eastern USA Time (Noon to 1:30pm West Coast Time).
Register here: https://bit.ly/3S7sXJ5
1 Like
Currently happening - seems pretty good. Join if you can.
Matt Kaeberlein starting presentation now…
it’s recorded - where are recordings posted after?
Not sure - I’ll ask when I can.
I will post the slides here - I’m doing screen captures.
“longevity intervention discovery has stagnated because hallmarks of aging”
““it’s hard to get funding for anything that does not target hallmarks of aging” => limited our ability to discover anything outside of it”
he’s bullish on reprogramming (impt b/c he’s known to be a skeptic)
1 Like
Matt Kaeberlein’s presentation:
On the last slide, Matt noted that there are in some compounds, synergistic effects both postive and negative. In this slide Metformin is the the “control” - with consistent positive results when used alone (this is in worms) of between 5% and 15%.
RapAdmin
split this topic
#10
Discussion:
Rapamycin - has a large effective dose range for lifespan improvement, 10 fold range, to perhaps 100 fold range.
Other drugs have very narrow dose range for longevity effectiveness.
Rapamycin Drug / Dog dosing - largely based on Mannick’s Everolimus studies.
I’m late to this posting. This graphic is interesting. Metformin seems to be a great drug for worms, and a great synergistic effects (on worms) with other pharmaceuticals.
